Online citations, reference lists, and bibliographies.
← Back to Search

IMP3/L523S, A Novel Immunocytochemical Marker That Distinguishes Benign And Malignant Cells: The Expression Profiles Of IMP3/L523S In Effusion Cytology.

K. Ikeda, G. Tate, T. Suzuki, T. Kitamura, T. Mitsuya
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Differentiating reactive mesothelial cells from metastatic carcinoma and malignant mesothelioma is critical in effusion cytology. Numerous immunohistochemical/cytochemical reports use various antibodies in effusion samples, and most antibodies differentiate metastatic adenocarcinoma from malignant mesothelioma, but no antibodies help distinguish malignant mesothelioma from reactive mesothelial cells. A mouse monoclonal antibody (IMP3/L523S) against KOC is a 580-amino acid oncofetal RNA-binding protein containing 4 K homology domains. IMP3/L523S has been identified in several human malignant tumors. The immunocytochemical staining profile of IMP3 was determined in 95% alcohol-fixed cytologic effusion specimens. A total of 229 cases of pleural and peritoneal effusion cytospecimens were evaluated for the study, including 39 benign effusions with reactive mesothelial cells and 190 metastatic malignant effusions. IMP3 immunoreactivity was observed in 2 (5.1%) of 39 cases of reactive mesothelial cells, 138 (72.6%) of 190 cases of malignant effusion, 4 (36.4%) of 11 cases of malignant mesothelioma, 106 (75.7%) of 140 cases of metastatic adenocarcinoma, and 8 (100%) of 8 cases of squamous cell carcinoma. The overall specificity for the diagnosis of malignancy was 94.9%, whereas the sensitivity was 72.6%. In the peritoneal effusions, the sensitivity for the diagnosis of metastatic adenocarcinoma to distinguish reactive mesothelial cells was 92.3%. In conclusion, IMP3 staining is present in many carcinomas and is not a useful marker for distinguishing between carcinomas arising in different organs. However, the IMP3 antibody is a highly specific marker for malignant lesions, and thus, IMP3 staining is useful for distinguishing neoplastic cells from reactive mesothelial cells in effusion samples.
This paper references
KOC is a novel molecular indicator of malignancy
F. Mueller (2003)
High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not.
Haodong Xu (2007)
Identification of two KH domain proteins in the alpha‐globin mRNP stability complex.
M. Kiledjian (1995)
Expression of the highly conserved RNA binding protein KOC in embryogenesis
F. Mueller-Pillasch (1999)
Cytomorphologic features of well‐differentiated papillary mesothelioma in peritoneal effusion: A case report
K. Ikeda (2008)
Spectrum of KOC (K homology domain containing protein overexpressed in cancer) immunostaining among carcinomas of different sites
S Istvanic (2005)
Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein
Friederike Müeller-Pillasch (1997)
Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not.
Rochelle A. Simon (2007)
Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data
J. King (2006)
A Family of Insulin-Like Growth Factor II mRNA-Binding Proteins Represses Translation in Late Development
J. Nielsen (1999)
Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma
Y. Kato (2007)
Utility of anti‐L523S antibody in the diagnosis of benign and malignant serous effusions
K. Hanley (2008)
Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
F. Roberts (2001)
Coordinate expression of cytokeratin 8 and cytokeratin 17 immunohistochemical staining in cervical intraepithelial neoplasia and cervical squamous cell carcinoma: an immunohistochemical analysis and review of the literature.
K. Ikeda (2008)
KOC (K Homology Domain Containing Protein Overexpressed in Cancer): A Novel Molecular Marker That Distinguishes Between Benign and Malignant Lesions of the Pancreas
R. Yantiss (2005)
KOC (K homology domain containing protein Overexpressed in Cancer) and S100A4‐protein immunoreactivity improves the diagnostic sensitivity of biliary brushing cytology for diagnosing pancreaticobiliary malignancies
Saverio Ligato (2008)
Conserved structures and diversity of functions of RNA-binding proteins.
C. Burd (1994)

This paper is referenced by
The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology.
J. Findeis-Hosey (2011)
Extracellular Vesicles-Based Drug Delivery Systems: A New Challenge and the Exemplum of Malignant Pleural Mesothelioma
Stefano Burgio (2020)
Accuracy of pleural effusion cytopathology
F. Rad (2012)
Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia
K. Kushitani (2016)
IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.
S. Hui (2018)
IMP3 Expression of the Cholangiocarcinoma in Cytology Specimen and Its Diagnostic Value
Jung Wook Yang (2010)
Role of biochemical analysis and cytopathologic presentation in diagnosis of malignant pleural effusion
F. Rad (2014)
How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.
A. Husain (2014)
Insulin‐like growth factor II mRNA‐binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma
S. Chen (2011)
IMP 3 Expression of the Cholangiocarcinoma in Cytology Specimen and Its Diagnostic Value
Jung Wook Yang (2010)
Markers of Oxidative stress in hypertension and Pleural effusion—Towards clinical application of free radicals and antioxidants
Subhankar Chakraborty (2012)
Value of Glut-1 and Koc Markers in the Differential Diagnosis of Reactive Mesothelial Hyperplasia, Malignant Mesothelioma and Pulmonary Adenocarcinoma / Reaktif Mezotel Hiperplazisi, Malign Mezotelyoma ve Akciğer Adenokarsinomu Ayırıcı Tanısında Glut-1 ve Koc’un Yeri
Özlem Üçer (2013)
Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma
S. Tschirdewahn (2019)
Young investigator challenge: MicroRNA‐21/MicroRNA‐126 profiling as a novel tool for the diagnosis of malignant mesothelioma in pleural effusion cytology
R. Cappellesso (2016)
Malignant pleural mesothelioma metastatic to the submandibular salivary gland, simulating glandular hypertrophy, diagnosed by fine-needle aspiration biopsy: a case report and literature review
M. Ambroggi (2014)
Prognostic value of tissue and circulating levels of IMP3 in prostate cancer
T. Szarvas (2014)
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
A. Husain (2018)
IMP3 and GLUT-1 Immunohistochemistry for Distinguishing Benign From Malignant Mesothelial Proliferations
A. Lee (2013)
Diagnostic usefulness of EMA, IMP3, and GLUT‐1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations
K. Ikeda (2011)
Can novel adipokines, asprosin and meteorin-like, be biomarkers for malignant mesothelioma?
N. Kocaman (2019)
MicroRNAs – novel biomarkers for malignant pleural effusions
Wiktor Wojczakowski (2019)
Combined detection of p16(INK4a) and IMP3 increase the concordance rate between cervical cytologic and histologic diagnosis.
Qingzhu Wei (2013)
Insulin-Like Growth Factor-II mRNA-Binding Protein 3 Expression in Effusion Cytology: A Marker for Metastatic Adenocarcinoma Cells and a Potential Prognostic Indicator in Gastric Adenocarcinoma
H. Kim (2014)
Tissue and Circulating Biomarkers in Mesothelioma
Paolo Andrea Zucali (2019)
Pathological Diagnosis of Mesothelioma
G. Fontanini (2019)
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.
A. Husain (2013)
Differential diagnosis of metastatic tumors
T. Elsheikh (2015)
The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review.
G. Alí (2018)
Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?
J. Bell (2012)
Hepatic Mesotheliomas and Related Neoplasms
A. Zimmermann (2016)
β-catenin expression in benign and malignant pleural disorders.
W. Anani (2011)
IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues
Christoph M. Burdelski (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar